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a  b  s  t  r  a  c  t
Parkinson’s  disease  (PD)  manifests  clinically  as  bradykinesia,  rigidity,  and  development  of a resting
tremor,  primarily  due  to degeneration  of  dopaminergic  nigrostriatal  pathways  in  the  brain.  Intrani-
gral  administration  of  the  irreversible  ubiquitin  proteasome  system  inhibitor,  lactacystin,  has  been  used
extensively  to model  nigrostriatal  degeneration  in  rats,  and  study  the  effects  of  candidate  neuropro-
tective  agents  on the  integrity  of the  dopaminergic  nigrostriatal  system.  Recently  however,  adjacent
extra-nigral  brain  regions  such  as  the  ventral  tegmental  area  (VTA)  have  been  noted  to  also  become
affected  in  this  model,  yet  their  integrity  in  studies  of  candidate  neuroprotective  agents  in  the  model  have
largely been  overlooked.  Here  we  quantify  the extent  and  distribution  of  dopaminergic  degeneration  in
the VTA  of  rats  intranigrally  lesioned  with  lactacystin,  and  quantify  the  extent  of  VTA  dopaminergic  neu-
roprotection  after  systemic  treatment  with  an  epigenetic  therapeutic  agent,  valproate,  shown  previously
to  protect  dopaminergic  SNpc  neurons  in this  model.  We  found  that  unilateral  intranigral  administra-
tion  of  lactacystin  resulted  in  a 53.81%  and  31.72%  interhemispheric  loss  of  dopaminergic  SNpc  and
VTA  neurons,  respectively.  Daily  systemic  treatment  of  lactacystin  lesioned  rats  with  valproate  however
resulted  in  dose-dependant  neuroprotection  of  VTA  neurons.  Our ﬁndings  demonstrate  that  not  only
is  the VTA  also  affected  in  the  intranigral  lactacystin  rat  model  of  PD,  but  that this  extra-nigral  brain
region  is  substrate  for neuroprotection  by  valproate,  an  agent  shown  previously  to  induce  neuroprotec-
tion  and  neurorestoration  of  SNpc  dopaminergic  neurons  in  this  model.  Our  results  therefore  suggest
that  valproate  is a  candidate  for extra-nigral  as  well  as intra-nigral  neuroprotection.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BYAbbreviations: PD, Parkinson’s disease; SNpc, Substantia Nigra pars compacta;
Syn, -synuclein; VTA, ventral tegmental area; UPS, ubiquitin proteasome sys-
ems; HAT, histone acetyltransferase; HDAC, histone deacetylase; HDACI, histone
eacetylase inhibitor; TH, tyrosine hydroxylase.
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1. Introduction
Parkinson’s disease (PD) is a complex movement disorder clas-
sically characterised by clinical presentation of rigidity, tremor
and bradykinesia, primarily resulting from degeneration of the
dopaminergic nigrostriatal pathway [10]. Degenerating dopamin-
ergic neurons within the Substantia Nigra pars compacta (SNpc)
of PD patients display intracytoplasmic protein inclusions, known
as Lewy bodies and Lewy neurites, composed predominantly of a
misfolded synaptic protein called -synuclein (Syn) [30]. As PD
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Animal study design.
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acta(−)VPA(++)) remained surgically naïve.
evelops this Syn pathology is thought to progressively spread
ostrally throughout the brain, gradually affecting higher order
entres with disease progression, bringing about dementia and
europsychiatric symptoms which are synonymous with late stage
D [2].
It has recently been suggested that the misfolding of Syn is
elf-propagating, spreading from neuron to neuron via a ‘prion-like’
echanism [16,18]. The concept of spreading Syn pathology in PD,
articularly by direct transfer of Syn between neurons suggests
hat there would be neuronal cell death in regions spatially nearby
he SNpc, where Syn pathology in PD is most evident. The SNpc
ies just lateral to another dopaminergic centre, the ventral tegmen-
al area (VTA), which like the SNpc has reciprocal projections to
audal nuclei, such as mesocortical projections to the prefrontal,
rbitofrontal and cingulate cortices [23]. Spread of Syn pathology
n the brain and the proximity of the SNpc to the VTA would suggest
hat this region is also affected in PD. Correspondingly, it has previ-
usly been shown that this is the case in PD: VTA neuron numbers
eing reduced in PD brains compared to control [9,28] thought,
ossibly to be related to duration or severity of depression in PD
atients as these neurons normally function as part of the brain’s
ositive affect system, in reward or reinforcement processes [6].
Toxin based models of PD tend to focus exclusively on nigros-
riatal neurodegeneration and although the SNpc and striatum are
bvious regions of interest, such study designs do not consider the
rogressive nature of PD in which several neuronal systems gradu-
lly become affected. A recent animal model of PD takes advantage
f the irreversible ubiquitin proteasome system (UPS) inhibitor,
actacystin, to model parkinsonian nigrostriatal neurodegenera-
ion by causing intracytoplasmic accumulation of altered proteins
19,20] and degeneration of dopaminergic and non-dopaminergic
Npc neurons [12]. Additionally however, when injected into the
Npc of rats, lactacystin has recently been observed to produce both
ntra- as well as extra-nigral pathology: affecting nearby regions
uch as the pedunculopontine nucleus (PPN) [26], the VTA [17]
nd also more rostral regions such as the primary motor (M1) and
omatosensory cortices [32]. It remains unanswered however as
o whether these neuronal populations susceptible to lactacystin
nduced cell death are also substrates for neuroprotective therapies
nown to successfully target nigrostriatal dopaminergic neurons in
his model.
In healthy cells, histone acetylation is carefully controlled by the
ctivity of two enzyme classes: histone acetyltransferases (HATs)
hich acetylate histone N-terminal tails, and histone deacetylases
HDACs) which deacetylase histone N-terminal tails. It was dis-
overed recently that Syn ‘masks’ histone proteins, preventing
heir acetylation, and as such the resulting histone hypoacety-
ation is thought to contribute to neurodegeneration in PD [14].
n addition it has been observed that a misbalance in the activ-
ties of HATs and HDACs exists in neurodegenerative scenarios,
eading to an exacerbation of the histone hypoacetylation and asso-
iated apoptosis [29]. We therefore postulate that this deregulation
f the balance of histone acetylation and deacetylation could be intranigrally injected with lactacystin. Control groups (Lacta(−)VPA(−) and
rectiﬁed with the use of HDAC inhibitors (HDACIs), to reduce the
neurodegeneration observed as a result of histone hypoacetylation
in PD [8]. Correspondingly, we  have shown recently that systemic
treatment with valproate, an inhibitor of HDAC classes I (HDACs
1–3 & 8) and IIa (HDACs 4, 5, 7 & 9), causes neuroprotection and
neurorestoration of dopaminergic neurons within the SNpc of lac-
tacystin lesioned rats [7]. The SNpc is known to express HDACs
2–5 and 11 most abundantly, as does the VTA [3]. Therefore, if val-
proate is to cause protection/restoration of neurons in the SNpc by
inhibition of HDACs it would therefore be likely that valproate also
protects against lactacystin induced neurodegeneration in the VTA.
In this study, we ﬁrstly aim to quantify the effect of a nigral
proteasome inhibitor lesion on the integrity of the nearby VTA in
the rat brain, with speciﬁc focus on the extent and distribution
of dopaminergic neuronal toxicity within this region. Secondly we
seek to determine whether or not dopaminergic VTA neurons, like
SNpc neurons, are a substrate for valproate mediated neuroprotec-
tion/restoration in this proteasome inhibitor model of PD.
2. Materials and methods
2.1. Experimental animals
Animal procedures were carried out in accordance with the
Home Ofﬁce Animals (Scientiﬁc Procedures) Act, UK, 1986 and
were previously approved by the Imperial College Animal Welfare
and Ethical Review Board. Male Sprague-Dawley rats (260 ± 10 g,
Charles River, UK) were housed in groups of two  or three at 21 ± 1 ◦C
on a 12 h light–dark cycle with the relative humidity maintained
at 55 ± 10%. Standard rat chow and drinking water were available
ad libitum throughout the duration of the study, and were supple-
mented with standard rat wet diet for seven days post-surgery.
2.2. Animal treatment groups
Six animal treatment groups were included in the study
(Table 1): four groups which received intranigral injection of
lactacystin and were either culled 7 days post-surgery, or subse-
quently treated for 28 days with either saline or valproate (200
or 400 mg/kg) administered i.p. starting 7 days post-surgery, and
two groups which remained surgically naïve whilst receiving sub-
sequent treatment with either saline or valproate (400 mg/kg). See
Fig. 1 for study design.
2.3. Stereotaxic lesioning of the SNpc with lactacystin
The left SNpc was stereotaxically lesioned using the irreversible
proteasome inhibitor lactacystin (Enzo Life Sciences, Exeter, UK)  as
previously described by us [7,26] and others [5,22,31–33]. Brieﬂy,
isoﬂurane (IsoFlo®, Abbot Laboratories, Maidenhead, UK)  anaes-
thetised animals were positioned in a stereotaxic frame (Kopf
Instruments, Tujunga, USA) in the horizontal skull position, and
a midline incision made in the scalp to expose the skull, where
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Table 1
Animal treatment groups.
Group N= Intranigral injection Daily i.p. injectionsa
Lacta(−)VPA(−)  7 None Saline
Lacta(−)VPA(++) 6 None Valproate (400 mg/kg)
Lacta(+)VPA(−)  7 Lactacystin (10 g in 4 l saline) Saline
Lacta(+)VPA(+) 6 Lactacystin (10 g in 4 l saline) Valproate (200 mg/kg)
Lacta(+)VPA(++) 6 Lactacystin (10 g in 4 l saline) Valproate (400 mg/kg)
Lacta(+) Week1 6 Lactacystin (10 g in 4 l saline) None (culled 1 week post-lesion)
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n  saline; 200 mg/kg valproate injections given as 2 ml/kg of 100 mg/ml solution of 
regma was identiﬁed [24]. A small burr hole was made in the skull
bove the SNpc and 10 g of lactacystin (2.5 g/l  in sterile (0.9%)
aline, 4 l in total) was stereotaxically administered via a Hamil-
on syringe to the SNpc: anterio-posterior, −5.2 mm,  medio-lateral,
2.5 mm and ventral to dura, −7.6 mm [24]. The lactacystin was
njected at a rate of 1 l/min, the needle was left in situ for 3 min
efore being retracted. The wound was sutured closed and animals
eft to recover in a heated recovery chamber before being returned
o their home cages.
.4. Tissue collection and preparation
At the end of the study period, animals were sacriﬁced, decap-
tated and the brain removed from the skull. Brains were ﬁxed in
% paraformaldehyde in phosphate buffered saline (PBS) (pH 7.4)
or 72 h before being cryoprotected in 30% sucrose in PBS until the
issue was observed to have sunk. Blocks were then snap frozen
n isopentane pre-chilled on dry ice and stored at −80 ◦C for sub-
equent sectioning. 30 m thick coronal sections were collected
hroughout the extent of the SNpc and VTA onto SuperFrost® Plus
lides (VWR international, Lutterworth, UK) using a cryostat (Bright
nstruments, Huntingdon, UK). Slides were then stored at −80 ◦C
ntil immunohistochemical staining.
.5. Immunohistochemistry
Immunohistochemistry for tyrosine hydroxide (TH), the rate
imiting enzyme in monoamine synthesis was utilised as the cel-
ular marker for dopaminergic neurons in the SNpc and VTA, and
resyl violet was used as a counterstain for the Nissl body of all neu-
ons. For this the avidin–biotin complex (ABC)/peroxidase method
f immunohistochemistry with a cresyl violet counterstain was
erformed similar to that previously published by our group [7].
rieﬂy, endogenous peroxidase activity and non-speciﬁc binding
ere blocked with H2O2 and normal goat serum respectively, prior
o incubation of tissue sections with the primary antibody (Rab-
it Polyclonal Anti-Tyrosine Hydroxylase, Millipore, MA,  USA) at
:1000. Sections were then incubated with the secondary antibody
Biotinylated Goat Anti-Rabbit Secondary Antibody, VectorLabs,
eterborough, UK) at 1:200 before being washed an incubated
ith ABC (Vectastain Elite ABC Kit, VectorLabs). Staining was then
isualised with 3,3′-diaminobenzidine (DAB) prior to being coun-
erstained with cresyl violet, dehydrated and coverslipped.
.6. Quantiﬁcation of SNpc and VTA neurons
Images of each section containing either the SNpc or VTA
ere acquired using ImagePro7 software (MediaCybernetics Inc.,
ethesda, MD,  USA) and captured using a Nikon Eclipse E1000 M
icroscope/digital camera system (Nikon Instruments, Surrey, UK)t 10× magniﬁcation. The SNpc and VTA were both delineated man-
ally referring to previously published morphological boundaries
nd a rat brain atlas [4,24] to create an area of interest (AOI). Counts
f both the TH positive (TH+) and Nissl positive (Nissl+) cells were; 400 mg/kg valproate injections given as 2 ml/kg of 200 mg/ml solution of valproate
ate in saline.
made of the entire AOI in both hemsipheres using ImageJ (v1.4,
National Institutes of Health, Bethesda, MD,  USA). An adaptation of
the optical fractionator method of stereological cell number estima-
tion was  utilised in accordance with previously published protocols
[34]. For this, every 6th section in the series containing the AOI
was analysed giving a section sampling fraction (ssf) of 1/6. A Hei-
denhain microcator (Hedenhain, Traunreut, Germany) attached to
a Nikon Eclipse E800 microscope (Nikon Instruments) with a JVC
3CCD camera (JVC, London, UK) was used to determine the height
sampling fraction (hsf): measuring the section height of three ran-
dom points within each AOI to give a mean section thickness. For
calculation of the total cell estimates (N), the following equation
was used, where n is the number of cells manually counted [34]:
N = n
(
1
hsf
)  (
1
ssf
)
2.7. Statistical analysis
Paired t-tests allowed comparison of SNpc and VTA cell loss in
lactacystin lesioned animals. A two  way  ANOVA with Bonferroni
post-test was  used to compare cell numbers between hemispheres
at each level of the VTA. Paired t-tests allowed comparison of cell
counts in the ipsilateral and contralateral hemispheres for both cell
types. A one way ANOVA with Bonferroni post-test was  used to
compare cell loss percentages between experimental groups. All
data is presented as mean ± standard error of mean. All statistical
tests were performed using GraphPad Prism (v5.0 for Windows,
GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Extent and distribution of TH+ and Nissl+ cell loss in the VTA
of intranigrally lesioned rats
As expected, intranigral lesioning with lactacystin resulted in a
marked interhemispheric loss of TH+ and Nissl+ positive cells in the
SNpc, observed 7 days post-lesion (Fig. 2B and C, % interhemispheric
loss in the SNpc of TH+ and Nissl+ cells, week 1, 45.17 ± 10.95%
and 39.50 ± 10.47%, respectively). This interhemispheric loss in the
SNpc was modestly exacerbated, 5 weeks post-lesion (TH+ and
Nissl+ cells loss, 1.19 and 1.39 fold increase from week 1). The VTA
however, exhibited only a subtle interhemispheric loss of dopamin-
ergic neurons, 7 days post-lesion, (Fig. 2B and C, % interhemispheric
loss in the VTA of TH+ and Nissl+ cells, week 1, 11.94 ± 2.12% and
12.83 ± 9.24%, respectively) which was  then markedly exacerbated
5 weeks post-lesion (TH+ and Nissl+ cells loss, 2.66 and 2.47 fold
increase from week 1). However this loss in the VTA at week 5 was
far less than that observed in the SNpc (Fig. 2B and C, % interhemi-
spheric loss in the VTA of TH+ and Nissl+ cells, 22.10 and 23.25%
less than that in the SNpc, respectively).
At week 5, in all caudorostral levels of the VTA examined, fewer
TH+ and Nissl+ cells were observed in the lesioned hemisphere
compared to the unlesioned hemisphere (Fig. 2D and E). However
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Fig. 2. Lactacystin induced loss of TH+ and Nissl+ cell loss in the VTA.
(A) Representative image of TH immunohistochemistry within the brain showing proximity and discrimination of the SNpc from the VTA. Mean percentage interhemispheric
(ipsilateral lesioned vs. contralateral non-lesioned hemisphere) loss of (B) TH+ cells and (C) Nissl+ cells in the SNpc and VTA of lactacystin (10 g) lesioned animals, 1 and 5
weeks  post-lesion. Distribution of (D) TH+ and (E) Nissl+ cell loss at each rostrocaudal level of the VTA in intranigral lactacystin lesioned animals, 5 weeks post-lesion. Each level
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igniﬁcance indicated with asterisks: *p < 0.05, **p < 0.01. n = 6/7 per group. Scale bar
ontralateral Substantia Nigra pars compacta; iVTA, ipsilateral ventral tegmental ar
his interhemispheric loss of TH+ cells in the VTA was  most evident
n the centre of the nucleus where numbers of TH+ cells are greatest
TH+ VTA cells at −5.76 mm from bregma, ipsilateral, 332 ± 21 vs.
ontralateral, 480 ± 41 cells, 27.95 ± 4.86% interhemispheric loss,
 < 0.05). Similar was the case with interhemispheric loss of Nissl+
ells: greatest loss being observed at −5.56 and −5.76 mm from
regma (27.56 ± 4.70% and 31.27 ± 2.23% interhemispheric loss of
issl+ cells observed at −5.56 and −5.76 mm from bregma respec-
ively, p < 0.01 in both comparisons).
.2. Valproate mediated neurorestoration of TH+ and Nissl+ VTA
eurons
No interhemispheric cell loss in the VTA was observed in either
urgically naïve saline treated, or surgically naïve valproate treated,
ontrol animal groups (Figs. 3 and 4, mean total of TH+ cells in
he VTA, 32,838 ± 3624). These numbers compared favourably to
hose previously published [21]. As noted above, in animals intran-
grally lesioned with lactacystin, and treated for 28 days with saline,
here was a signiﬁcant interhemispheric loss of both TH+ and Nissl+
ells in the VTA (Fig. 4, 31.71 ± 5.94 and 31.63 ± 5.79% interhemi-
pheric loss, respectively). Animals lesioned with lactacystin which
eceived subsequent treatment with valproate however displayed
ose dependant protection of both TH+ and Nissl+ neurons in the
TA (Fig. 4C and D, interhemispheric loss of TH+ cells, 13.87 ± 5.73%of the intranigral injection of lactacystin. Data presented as mean ± SEM. Statistical
 to 500 m.  Abbreviations: iSNpc, ipsilateral Substantia Nigra pars compacta; cSNpc,
TA, contralateral central ventral tegmental area.
and 2.03 ± 1.56% loss in 200 mg/kg and 400 mg/kg valproate treated
animals respectively). This interhemispheric loss of TH+ neurons
in animals treated with 400 mg/kg valproate reached signiﬁcance
from that in saline treated (p < 0.001). Similarly, interhemispheric
loss of Nissl+ neurons was  signiﬁcantly greater in saline treated
animal compared to both 200 mg/kg valproate treated animals
(p < 0.05) and 400 mg/kg valproate treated animals (p < 0.001).
4. Discussion
We have shown here that intranigral injection of the irreversible
proteasome inhibitor, lactacystin, in rats results in not only a sig-
niﬁcant degree of dopaminergic cell loss in the SNpc but also in
the adjacent VTA. This loss of neurons in the VTA in this model
is sustained throughout the entirety of the nucleus: the largest
degree of cell loss appearing in the centre of the structure where
cell numbers are greatest. Like the dopaminergic neurons of the
SNpc, as we have previously published [7], we also show here that
the lactacystin induced degeneration of dopaminergic neurons in
the VTA is also dose dependantly ablated upon systemic treatment
with the HDACI, valproate, suggesting that valproate is a candidate
for both intra- and extra-nigral neuroprotection. Importantly, to
our knowledge, this is the ﬁrst study on the impact of a candidate
neuroprotective agent on the integrity of the VTA in this animal
20 I.F. Harrison et al. / Neuroscience Letters 614 (2016) 16–23
F
R roup:
( udal t
m
o
s
n
t
u
n
p
s
[
a
m
r
n
e
m
m
t
s
u
tig. 3. Micrographs demonstrating loss and protection of TH+ cells in the VTA.
epresentative example images of the TH and Nissl stained VTA in each treatment g
E)  Lacta(+)VPA(+); (F) Lacta(+)VPA(++). All sections are approximately −5.8 mm ca
odel of PD: all previously published studies justiﬁably focussing
n dopaminergic nigrostriatal integrity.
The irreversible proteasome inhibitor, lactacystin, has been
hown extensively to recapitulate parkinsonian dopaminergic
euronal cell death, when stereotaxically injected into the nigros-
riatal system of rats [15,19,22,26,31], resulting in formation of
biquitin/Syn immunopositive inclusions in nigral dopaminergic
eurons [15,19,22,26,31]. This intracellular accumulation of altered
roteins results in progressive nigral neurodegeneration and sub-
equent progressive development of motor behavioural deﬁcits
31,32]. These behavioural symptoms have also been observed to be
ttenuated with chronic l-DOPA treatment [13]. Therefore, unlike
any other animal models of PD, the lactacystin model not only
ecapitulates the formation of protein inclusions in dopaminergic
eurons, but also models the progressive nature of both dopamin-
rgic neurodegeneration and development of l-DOPA attenuated
otor behavioural deﬁcits. These qualities make the lactacystin rat
odel of PD and ideal platform on which to study the neuroprotec-
ive potential of candidate therapeutics, allowing for simultaneous
tudy of motor behaviour, neuropathology, and cellular and molec-
lar changes in a single animal model.
As the lactacystin model becomes increasingly used in
he ﬁeld, more recently, focus has turned to the effects of (A) Lacta(+) Week1; (B) Lacta(−)VPA(−); (C) Lacta(−)VPA(++); (D) Lacta(+)VPA(−);
o bregma. Scale bar equal to 500 m.
intranigral lactacystin on the integrity of adjacent neuronal pop-
ulations [12,17,26,32]. The PPN, which lies just rostral to the
SNpc, contains a mixed neuronal population of glutamatergic, -
aminobutyric acid (GABA)-ergic and cholinergic neurons [27]. We
showed recently that rats intranigrally injected with lactacystin
displayed a marked loss of cholinergic neurons in the PPN [26].
Additionally, in this animal model Mackey et al. [17] have also stud-
ied the integrity of the VTA, which lies just lateral to the SNpc,
demonstrating increased degeneration of dopaminergic VTA neu-
rons with increasing dose of intranigral lactacystin. Importantly,
consistent with their ﬁndings, we  show here that the loss of VTA
dopaminergic neurons in the model is less severe than in the SNpc.
This relative vulnerability to UPS inhibition of the dopamine pro-
ducing cells in the SNpc compared to those in the VTA is also
consistent with post-mortem ﬁndings in human PD in which Syn
pathology affects dopaminergic neurons earlier in the course of dis-
ease than the VTA [2]. A number of differences exist between the
dopaminergic neurons of the SNpc and those of the VTA, which
could attribute to this relative vulnerability observed clinically and
in this rodent model of PD. Firstly, dopaminergic neurons within
the SNpc have typically 2–5 dendrites emanating from the poles of
the neuron [1,11], whereas dopaminergic neurons of the VTA have
3–5 dendrites emanating from the soma that extend in a radial array
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Fig. 4. Valproate treatment causes dose-dependant protection of dopaminergic neurons in the VTA in lactacystin lesioned animals.
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actacystin (10 g) rat model of Parkinson’s disease. This is exempliﬁed by the p
emispheres of the VTA. Data presented as mean ± SEM. Statistical signiﬁcance ind
rom the soma, probably due to the lack of spatial constraints in the
TA [1,11]. Electrophysiologically, neither class of neuron differ in
heir tonic and burst ﬁring rates, however VTA neurons exhibit a
ower amplitude of slow oscillation in ﬁring rate, compared to SNpc
eurons, perhaps attributing to their reduced vulnerability in PD.
In the current study, degeneration was observed only in the
psilateral VTA. However in contrast to this Mackey et al. [17]
ave previously demonstrated bilateral VTA degeneration in ani-
als unilaterally injected with 10 g lactacystin. Similarly, they
bserve a far greater degree of both ipsilateral VTA and SNpc degen-
ration at this dose. A number of differences exist between the
tudy by Mackey et al., and ours however, which could attribute
o the discrepancy in ﬁndings. The volume and concentration of
he lactacystin containing solution was identical between studies
owever the coordinates used for intranigral injection were dif-
erent (current study: AP −5.2 mm,  ML  +2.5 mm,  VD −7.6; Mackey
t al. [17]: AP −5.5 mm,  ML  −2 mm,  DV −7.5). Of note to the VTA,
he medio-lateral coordinate previously used by Mackey et al.,
s far closer (0.5 mm)  to the midline, and it is therefore possible
hat injection of lactacystin at this location could attribute for the
ncreased susceptibility of both the ipsilateral, and contralateral
TA to degeneration. Likewise, the stereotaxic brain atlas used as
eference for these coordinates is noted only to be used for ani-
als weighing between 250 and 350 g [24]. The animals used in
he study by Mackey et al., are far larger than this (350–550 g), and
iven the known inaccuracy of brain stereotaxic coordinates when
pplied to animals outside of this weight range [25], it suggests that
his may  account for some of the differences in ﬁndings between
tudies of this intranigral dose of lactacystin. Lastly, the extent of
TA degeneration in the study by Mackey et al., was  quantiﬁed
–10 weeks after lactacystin lesioning, as opposed to 5 weeks in
he current study. Lactacystin is an irreversible UPS inhibitor and
herefore it is thought that its neurodegenerative affect would con-
inue, again possibly explaining the discrepancy between our, and
ackey et al., studies.
We  recently suggested that either transport or diffusion of the
njected lactacystin may  be responsible for toxicity in the nearby
PN, due to our observations of greater cell loss and neuronal a dose-dependant neuroprotective/restorative effect of valproate in the intranigral
age interhemispheric loss of TH+ (C) and Nissl+ (D) neurons calculated between
 with asterisks: *p < 0.05; **p < 0.01, ***p < 0.001. n = 6/7 per group.
atrophy in the rostral (side closest to the SNpc) compared to the
caudal PPN [26]. In the current study however degeneration in the
VTA was observed throughout the entirety of the structure: not
focussed to the anterio-posterior level closest to the SNpc injection
but to the centre of the structure where cell numbers are great-
est. Moreover in the current study, lactacystin injection into the
SNpc was conducted at a very low infusion rate, of just 1 l/min,
with the aim of limiting the free diffusion and mislocalisation of
the toxin from site of injection. Similarly, post-injection, the nee-
dle was  left in situ for three minutes, with the aim of limiting efﬂux
of the toxin from the needle tract upon needle retraction and ensur-
ing complete lactacystin absorption into the SNpc. This therefore
suggests that the previous postulation of either transport or diffu-
sion of lactacystin to nearby nuclei, affecting their integrity, is not
responsible for intranigral lactacystin induced degeneration in the
VTA observed here suggesting that mechanisms other than trans-
port or diffusion of the toxin to nearby nuclei are responsible for
spreading pathology. Further work is therefore required in order to
understand how the spread of pathology observed in the current
study is achieved.
Intracellular Syn accumulation has been observed to actively
promote histone hypoacetylation both in vitro in SH-SY5Y cells
and in vivo in drosophila, both overexpressing Syn [14]. This is
thought to be achieved through Syn ‘masking’ histone proteins,
preventing their acetylation by HATs [14]. Notably we  showed
recently, that in line with its effects on Syn accumulation in vivo,
intranigral injection of lactacystin caused a signiﬁcant reduction
in histone acetylation in the brain [7]. Furthermore, this was
able to be dose dependantly reversed upon treatment with the
HDACI, valproate, translating to upregulation of neurotrophic and
neuroprotective factors, and neuroprotection and restoration of
degenerating dopaminergic neurons in the lesioned SNpc [7]. In
these same animals, in the current study we demonstrate that
dopaminergic neurons in the VTA too are subject to neuroprotec-
tion by treatment of the animals with valproate. The SNpc itself
expresses HDACs 2–5 and 11 most abundantly [3], the majority of
which are inhibited by valproate, an inhibitor of HDAC classes I
(HDACs 1–3 & 8) and IIa (HDACs 4, 5, 7 & 9). The VTA expresses a
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imilar proﬁle of HDAC isoform expression to the SNpc, suggesting
hat if neuroprotection can be achieved through valproate’s inhi-
ition of classes I and IIa in the SNpc, then the neuroprotection
bserved in the VTA may  also be achieved via this mechanism.
owever, further analysis of the HDAC isoform expression pro-
le of VTA dopaminergic neurons, and this cell type’s response
o valproate treatment in terms of its histone acetylation status,
eeds to be performed in order to unambiguously suggest that
hey are subject to neuroprotection by HDAC inhibition. Likewise,
alproate is a somewhat promiscuous drug: affecting GSK-3 and
kt/ERK pathways, GABA/glutamate neurotransmission, Na+ and
a2+ voltage-dependant channels, phosphoinositol/TCA pathways
nd the oxidative phosphorylation pathway [35]. A number of
hese effects too could contribute towards valproate’s neuropro-
ective phenotype observed here and hence their involvement in
his experimental setting should also be investigated in order to
ule them out of the neuroprotective phenotype observed here.
. Conclusions
We  show here that intranigral injection of the irreversible pro-
easome inhibitor, lactacystin, causes not only neurodegeneration
ithin the SNpc itself, but also extensively within the nearby VTA,
 weeks post-lesion. The extent of degeneration observed in both
f these regions demonstrate that this animal models well the
xtent of degeneration observed in the SNpc and VTA in human PD.
dditionally, we demonstrate here that like neurons of the SNpc,
egenerating dopaminergic neurons within the VTA are also a sub-
trate for neuroprotection by the HDACI, valproate. These ﬁndings,
long with those previously published; suggest that the lactacystin
at model of PD is an ideal model for the study of extranigral degen-
ration in PD with particular relevance for the study of the efﬁcacy
f neuroprotective drugs, designed initially for protection of SNpc
eurons, on extranigral structures.
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